Hepatorrenal syndrome: up ToDate
PDF (Español)
PDF

Keywords

Síndrome hepatorrenal
Insuficiencia renal
Cirrosis hepática
Tratamiento.

How to Cite

1.
Villanueva Bendek I. Hepatorrenal syndrome: up ToDate. Rev. Colomb. Nefrol. [Internet]. 2014 Jul. 1 [cited 2024 Jul. 16];1(2):118-29. Available from: https://revistanefrologia.org/index.php/rcn/article/view/183

Abstract

El síndrome hepatorrenal (SHR) es una complicación frecuente y severa en pacientes con cirrosis hepática e hipertensión portal y se caracteriza por anormalidades circulatorias que llevan a vasoconstricción renal, generando insuficiencia renal funcional.
Su fisiopatología ha sido estudiada y el pronóstico es reservado a menos que el paciente reciba trasplante hepático.
El tratamiento medicamentoso con vasoconstrictores esplénicos es la esperanza futura de estos pacientes mientras acceden a trasplante hepático.
https://doi.org/10.22265/acnef.1.2.183
PDF (Español)
PDF

References

1. Helwing FC, Scuhtz CB. A liver –Kidney sindrome. Clinical,pathological and experimental studies. Surg Gynecol Obst 1.932;55:570-580.

2. Wilensky AO. Occurrence, distribution and pathogenesis of so –called liver death and / or hepatorenal syndrome. Arch Surg 1939;38:625-631.

3. Epstein M. Effects of heart and liver disease and neoplasia on kidney and electrolyte metabolism. In: Massry & Glassok ´s. Textbook of nephrology. 4st ed. Baltimore: Williams& Wilkins, 2000:1067-1077.

4. Flint A. Clinical report on hydro- peritoneum based on a analysis of forty –six cases. Am J med Sci 1863;45:306-339.

5. Hecker R, Sherlock S, Electrolyte and circulatory changes in terminal liver failure. Lancet 1956;2:1221-1225.

6. Koppel MH, Coburn JN et al. Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functional nature of renal failure in advanced liver disease. N Engl J Med 1969;280:1367-1371.

7. Iwatsuki S, Popovtzer MM, et al. Recovery from “hepatorenal syndrome” after orthotopic liver transplantation. N Engl J med 1973;1973;289:1155-1159.

8. Paper S: Hepatorenal syndrome. In Epstein M (ed): The Kidney in Liver Disease, 2 nd ed. New York, Elsevier, 1983, p 87.

9. Shear L, Kleinerman J, Gabuzda GJ: Renal failure in patients with cirrhosis of the liver. I. Clinical and pathologic characteristics. Am J med 39:184,1965.

10. Bataller R, Gines P, Guevara M, Arroyo V. Hepatorenal syndrome. Semin Liver Dis 1997;17:233-248.

11. Bernardo DE, Summerskill WH, Strong CG, Baldus WP. Renal function, rennin activity and endogenous vasoactive substances in cirrhosis. Am J Dig Dis 1970;15:419–425.

12. Dibona GF. Renal nerve activity in hepatorenal syndrome. Kidney Int 1984;25:841-853.

13. Cupin W. Diagnosis and pathophysiology of hepatorenal syndrome. Available from: URL: http//:internet links (http://
www.hdcn.com/symp/02asnb/kup/kup.htm.

14. Bolton C, Barnard WG. The pathological occurrence of the liver in experimental venous stagnation. J Pathol Bacteriol 1931;34:701-706.

15. Papper S. The role of the kidney in Laennec´s cirrhosis of the liver. Medicine 1958;37:299-316.

16. Perera GA. The plasma volume in Laennec´s cirrhosis of the liver. Ann Intern Med 1946;24:643-648.

17. Lieberman FL, Denison EK, Reynolds TB. The relationship of plasma volume, hypertension portal, ascites and renal sodium, and water retention in cirrhosis: the “overflow” theory of ascitis formation. Ann N Y Acad Sci 1970;170:202-206.

18. Schier RW, Arroyo V Bernardi M, et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151-1157.

19. Ring-Larsen H . Renal blood flow in patients with hepatorenal syndrome. Scand J Clin Invest. 1977 Nov;37(7):635-42

20. Asbert M et al. Humoral response to cirrhosis .Gastroenterology .1993 May; 104(5):1485-91.

21. Ginés P, Fernández-Esparrach G, Arroyo V, Rodés J. Pathogenesis of ascitis in cirrhosis. Semin Liver Dis 1997;17:175-90.

22. Arroyo V, Ginés P, Jiménez W, Rodés J. Ascitis, renal failure and electrolyte disorders in cirrhosis. Pathogenesis, diagnosis and treatment. In : McIntyre N, Benhamou JP, Bircher J,et al, eds. Oxford: Oxford medical publications, 1991:429-470.

23. Laffi G, La Villa G, Pinzani M, et al. Arachidonic acid derivatives and renal function in liver cirrhosis. Semin Nephrol 1997;17:530-548.

24. Ros J, Jiménez W, Bosch-Marcé M, et al. Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis. Hepatology 1995;21:915-920.

25. Quintero E, Ginés P, Arroyo V, et al. Sulindac reduces the urinary excretion of prostaglandins and impairs renal function
in cirrhosis with ascitis. Nephron 1986;42:298-303.

26. Ginés P, Schrier RW. Hepatorenal Syndrome and renal dysfunction associated with liver disease. In: Schrier RW, Gottschalk CW, eds. Diseases of the kidney. Boston: Little, Brown and Co, 1997:2099-2127.

27. Paper S Belsky JL, Bleifer KH. Renal failure in Laennec´s cirrhosis of the liver. I. Description of clinical and laboratory features. Ann Intern Med 1959;51:759.

28. Epstein M: The Hepatorenal Syndrome. Emerging perspective of pathophysiology and therapy. J Am Soc Nephrol 1994;4:173594.

29. Epstein M, Oster JR, DeVelasco RE: Hepatorenal syndrome following hemihepatectomy. Clin Nephrology 1976;5:128.

30. Arroyo V, Ginés P, Gerbes A, et al. Definition and criteria diagnostic of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996;23:164-176.

31. Arroyo V, Rodés J. A rational approach to the treatment of ascitis. Postgrad Med J 1975;51:558-562.

32. Ginés J, Schrier RW. Hepatorenal Syndrome and renal dysfunction associated with liver disease. In: Schrier RW, Gottschalk CW, eds. Diseases of the kidney. Boston: Little, Brown and Co, 1997:2099-2127.

33. Ignatius KP. Hepatorenal Syndrome. In: Johnson RJ, Feehally J, eds. Comprehensive Clinical Nephrology. 1ed. Barcelona: Mosby; 2000,4:17.1-17.8.

34. Takabatake T et al. Discrepancy between creatinine clearance and rate filtration glomerular in patients with liver diseases. Arch Inter Med 1988 Jun;148(6):1313-1315.

35. Ginés P, Rodés J. Clinical disorders of renal function in cirrhosis with ascites. In: Arroyo V, Ginés P, Rodés J, Schrier RW. Ed. Ascites and renal dysfunction in liver disease1st ed. Massachusetts: Blackwell Science, Inc; 1999:36-62.

36. Horio M, Orita Y, Fukunaga M. Assessment of renal Function. In: Johnson RJ, Feehaly J, eds. Comprehensive Clinical Nephrology. 1st ed. Barcelona: Mosby; 2000;2:3.1-4.10.

37. Nadim MK, Kellum JA, Davenport A, Wong F, Davis C, Pannu N, Tolwani A, Bellomo R, Genyk YS; ADQI Workgroup. Hepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.Crit Care. 2012 Feb 9;16(1):R23.

38. Demirtas S, Bozbas A, Akbay A, et al. Diagnostic value of serum cystatina for evaluation of hepatorenal syndrome. Clin Chim Act .2001;311(2):81-89.

39. Eknoyan G. Glomerular abnormalities in liver disease. In: Epstein M, ed. The Kidney in liver disease. Baltimore: Williams& Wilkins. 1988:154-181.

40. Platt JF, Ellis JH, Rubin Jm, et al. Renal duplex doppler ultrasonography: a noninvasive predictor of kidney dysfunction and hepatorenal failure in liver disease. Hepatology 1994;20:362-369.

41. Gonwa TA, Morris CA, Goldstein RM, et al.: Long-term survival and function renal following liver transplantation in patients with and without hepatorenal syndrome- Experience in 300 patients. Transplantation. 1991;51:428.

42. Iwatsuki S, Popovtzer MM, Corman JL, et al: Recovery from hepatorenal syndrome after orthotopic liver transplantation. N Eng J Med 289:1155,1973.

43. Wood RP, Ellis D, Starzl TE. The reversal of the hepatorenal syndrome in four pediatric patients following successful orthotopic liver transplantation. Ann Surg 205:415,1987.

44. Ortega R, Calahorra B, Ginés P. Vasoconstrictores en el tratamiento del Síndrome Hepatorrenal. Nefrología 2002 .Vol XXII;S 5:56-61.

45. Wong F, Blendis L: New challenge of hepatorenal syndrome: prevention and treatment. Hepatology. 2001; 34:1242-1251.

46. Ginés A, Ginés P, Escorcell A, Arroyo V et al. Incidence , predictive factors and prognosis of hepatorenal syndrome in cirrhosis. Gastroenterology 1993;105:229-236.

47. Barnardo DE, Baldus WP, Maher FT. Effects of dopamine on renal function in patients with cirrhosis. Gastroenterology 1970;58:524-531.

48. Back Y, Gaudin C, Hadengue A, et al. Systemic, splanchnic and renal hemodynamic effects of dopaminergic dose dopamine in patients with cirrhosis. Hepatology 1991;14:483-487.

49. Wilson JR. Dopamine in hepatorenal syndrome. JAMA 1997;238:2719-2710.

50. Moore K. The Hepatorenal syndrome. Clinic Sci. 1997;92:433-443.

51. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with administration of midrodine and
octroetido. Hepatolgy 1999;29:1690-1697.

52. Sabat M, Villanueva C, Rosello J et al. Effect of subcutaneous administration of octreotido on endogenous vasoactive system and renal function in cirrhotic patient with ascites. Dig Dis Sci 1998;43:2184-2189.

53. Lenz K , Hortnagl H, Druml W , et al. Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Gastroenterology 1991;101:1060-1067.

54. Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin
and dopamine. Hepatology 1999;30:870-875.

55. Escorsell A, Bandi JC, Moitinho E, Rodés J, et al. Time profile of the hemodynamic effects of terlipressin in portal hypertension. J Hepatol 1997;26:621-627.

56. Ganne-Carrie N, Hadengue A, Benjamou JP. Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation. Dig Dis Sci. 1996;41:1054-1056.

57. Uriz J, Ginés P, Sort P, Jiménez W, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal
syndrome. J Hepatology 2000;33:43-48.

58. Mulkay JP, Louis H, Deviere J, et al. Long-term terlipresin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: pilot study. Acta gastroenterol Belg 2001;64:15-19.

59. Arroyo V, Bataller R, Guevara M. Treatment of hepatorenal yndrome in cirrhosis In: Arroyo V, Ginés P, Rodés J, Schrier RW eds. Ascites and renal dysfunction in liver disease 1st ed. Massachusetts: Blackwell Science, Inc; 1999:492-510.

60. Epstein M. Hepatorenal syndrome. In: Wolfe M eds. Therapy of digestive disorders. A companion to Sleisenger and Fortrans Gastrointestinal and liver disease, 1st ed .Philadelphia, Saunders Company, 2000:398-404.

61. Ellis D, Avner ED, Renal failure and dialysis therapy in children with failure hepatic in the perioperative period of orthotopic liver transplantation. Clin Nephrol 1986;25:295-303.

62. Epstein M, Perez GO. Continuous arteriovenous ultrafiltration in the management of the renal complications of liver disease. Int J Artif Organs. 1985;9:215-216.

63. Davenport A, Will EJ, Davison AM. Effect of renal replacement therapy on patients with combined acute renal and fulminant hepatic failure. Kidney Int Suppl. 1993 Jun;41:S 245-51.

64. Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patient with hepatic and renal failure. Crit Care Med. 1993 Mar;21(3):328-38.

65. Davenport A. The management of renal failure in patient at risk of cerebral edema/hypoxia. New Horiz. 1995 Nov; 3(4):717-24.

66. Iwai H, Naki M, Naito T, et al. Removal of endotoxin and cytokines by plasma exchange in patients with acute hepatic
failure. Crit Care Med. 1998 May;26(5):873-6.

67. Bellomo R, Baldwin I, Ronco C. Preliminary experience with high-volume hemofiltration in human septic shock. Kidney Int Suppl. 1998 May;66:S182-5.

68. Wong F, Blendis L. New Challenge of hepatorenal syndrome: prevention and treatment. Hepatolgy 2001;34:1242-1251.
No national or foreign publication may partially or totally reproduce or translate Revista Colombiana de Nefrología articles or abstracts without prior written permission from the journal’s Editorial Board.

Dimensions


PlumX


Downloads

Download data is not yet available.